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Abbreviations 
 
Acot1        Acyl-CoA thioesterase 1 
Acox1        Acyl-CoA oxidase 1 
ACSL         Long-chain acyl-CoA synthetase 
ATGL         Adipose triglyceride lipase 
BrMDMC      4-Bromomethyl-6,7-dimethoxycoumarin 
BSA           Bovine serum albumin 
CGI-58        Comparative gene identification-58 
CPT1a         Carnitine palmitoyltransferase 1a 
DGAT         Acyl-CoA:diacylglycerol acyltransferase 
FABP1         Fatty acid binding protein 1 
FABPpm       Plasma membrane-associated fatty acid binding protein 
FAT/CD36      Fatty acid translocase 
FATP          Fatty acid transport protein 
GPAT         Glycerol-3-phosphate acyltransferase 
LCAD         Long-chain acyl-CoA dehydrogenase 
MCAD        Medium-chain acyl-CoA dehydrogenase 
NAFLD        Nonalcoholic fatty liver disease 
PPARα        Peroxisome proliferator-activated receptor α 
TAG          Triacylglycerol 
TLC          Thin-layer chromatography 
VLDL         Very-low-density lipoprotein 
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Abstract.      Hepatic triacylglycerol (TAG) homeostasis is maintained by carefully 
regulated balance between its synthesis and disposal. Impairment in this balance causes 
steatosis. The aims of this study were (i) to uncover whether fibrates control TAG 
concentration through the action of adipose triglyceride lipase (ATGL) and (ii) to compare the 
potency of the effects on ATGL expression and TAG concentration among fenofibrate, 
bezafibrate and clofibric acid, in the liver of rats. Treatments of rats with the three fibrates 
induced ATGL and concomitantly decreased hepatic TAG concentration. The up-regulation of 
ATGL was likely mediated through the activation of peroxisome proliferator-activated 
receptor α. Fibrates also expanded capacity of fatty acid β-oxidation. Importantly, three fibric 
acids (fenofibric, bezafibric and clofibric acids) that are active metabolites formed in the liver 
exhibited almost the same potency to elevate ATGL expression in vivo, despite the fact that 
there were considerable differences in this regard among fenofibrate, bezafibrate and clofibric 
acid when compared on the basis of their dosage. These results suggest that ATGL represents 
a potential therapeutic target for ameliorating hepatic steatosis and that fibric acids are 
promising agents to ameliorate and/or protect against hepatic steatosis. 
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Introduction 
 
    Fibrates are well known as a class of drugs used to treat dyslipidemia, in particular 
hypertriglyceridemia. The primary clinical outcomes are decreased plasma triacylglycerol 
(TAG), increased low-density lipoprotein size, increased high-density lipoprotein synthesis 
and increased reverse cholesterol transport, thus reducing the risk of cardiovascular disease (1 
– 5). Moreover, there is increasing evidence with regard to the amelioration of insulin 
sensitivity, and vascular and systemic inflammation by fibrates (1, 3, 6). In hepatocytes, 
excessive accumulation of TAG is the common denominator of a wide range of 
pathophysiological entities known as hepatic steatosis or nonalcoholic fatty liver disease 
(NAFLD). Tight regulation between TAG synthesis, hydrolysis, secretion and fatty acid 
oxidation is required to prevent TAG accumulation in the liver. Therefore, understanding the 
pathway that regulates hepatic TAG metabolism in the liver is critical for the development of 
therapies to ameliorate pathophysiological conditions associated with excessive hepatic TAG 
accumulation, such as hepatic steatosis and NAFLD. However, it remains yet to be 
established whether fibrates ameliorate NAFLD (7, 8). This may be due to the fact that 
biochemical mechanism behind the effects of fibrates on the regulation and physiological 
function of adipose triglyceride lipase (ATGL) in TAG metabolism is not fully understood in 
the liver. 
Catabolism of TAG is believed to be initiated by the action of ATGL, which is known to 
catalyze the initial step in lipolysis by hydrolyzing TAG into diacylglycerol and free fatty acid 
(9). Consequently, it is most likely that functional deficiency of ATGL results in TAG 
accumulation in essentially all tissues and cells. ATGL has been demonstrated to be expressed 
in most tissues with the highest expression in adipose tissues but very low expression in the 
liver (9). Subsequent studies have identified ATGL as a major functional lipase in adipose 
tissue (10), whereas its role in the liver has been poorly understood. However, there is 
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evidence demonstrating that ATGL ablation leads to pronounced hepatic steatosis, whereas 
increasing ATGL production in the liver reduces hepatic steatosis in rodents (11 – 14). These 
findings suggest that ATGL plays a pivotal role in TAG metabolism in the liver and that ATGL 
represents a pharmacological therapeutic target for NAFLD. In this regard, it is of interest to 
understand in detail the effects of fibrates on ATGL in the liver. As far as we know, little study 
has been carried out in vivo on whether fibrates cause modification of ATGL function in the 
liver. There are several kinds of fibrates. Clofibrate (ethyl ester of clofibric acid) is a 
prototype of fibrates, but has been gradually replaced by more efficient drugs, like fenofibrate 
(isopropyl ester of fenofibric acid) and bezafibrate (also referred to as bezafibric acid). On the 
other hand, it is now considered that there are differences in the mode of actions among 
fibrates (15 – 17). However, fundamental information is lacking about the action of fibrates 
on hepatic ATGL, despite the fact that these drugs are the most promising agents for the 
therapy of hepatic steatosis. In this context, the present study aimed (i) to uncover whether 
fibrates regulate TAG concentration through the action of ATGL and (ii) to compare the 
potency of the effects on ATGL expression among fenofibrate, bezafibrate and clofibric acid 
in the liver of rats. 
 
Materials and Methods 
 
Materials 
Bezafibrate, clofibric acid, fenofibrate, phosphatidylcholine (from egg yolk), 
phosphatidylinositol (from soybean), triolein, 4-bromomethyl-6,7-dimethoxycoumarin 
(BrMDMC) and bovine serum albumin (BSA) were obtained from (Sigma-Aldrich Co., St. 
Louis, MO, USA); 18-crown-6-ether from Wako Chemicals (Osaka); anti ATGL (F-7) mouse 
monoclonal IgG from Santa Cruz Biotechnology, Inc., (Dallas, TX, USA); anti mouse IgG 
HRP-linked antibody from Cell Signaling Technology, Inc., (Danvers, MA, USA). Triolein 
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[carboxyl-14C] (108.8 mCi/mmol) was purchased from PerkinElmer (Waltham, MA, USA), 
and was purified by thin-layer chromatography (TLC) on silica gel G plates, which were 
developed with n-hexane/diethyl ether/acetic acid (80:30:1, by vol.). The regions that 
corresponded to TAG were scraped off and transferred to a tube. [14C]TAG was extracted 
from silica gel as described previously (18). 
 
Animals 
All animal procedures were approved by Josai University’s Institutional Animal Care 
Committee in accordance with the Guidelines for Proper Conduct of Animal Experiments 
(Science Council of Japan). Male Wistar rats were obtained from SLC (Hamamatsu). The 
animals were fed on a standard diet (CE-2; Clea Japan Inc., Tokyo) ad libitum and allowed 
free access to water. After acclimatization for at least 1 week, rats aged 8 weeks were fed on a 
diet admixed with fenofibrate, bezafibrate or clofibric acid. To examine the dose-response 
effects, the rats were fed on a diet containing various concentrations of fenofibrate (0, 0.025, 
0.05, 0.1 or 0.2% (w/w)), bezafibrate (0, 0.025, 0.05, 0.1 or 0.2% (w/w)) or clofibric acid (0, 
0.05. 0.1, 0.15, 0.2 or 0.3% (w/w)) for 14 days. Food consumption by each rat was measured 
and the amounts of fibrates taken in by each rat were calculated. In time-course experiments, 
the rats were fed on a diet containing 0.1% (w/w) fenofibrate, 0.1% (w/w) bezafibrate or 0.3% 
(w/w) clofibric acid for 0, 2, 7 or 14 days. Under diethyl ether anesthesia, blood was 
withdrawn from the inferior vena cava and serum was prepared. The liver was rapidly 
removed, washed with saline and weighed. It was then divided into small portions, frozen in 
liquid nitrogen and stored at -80°C for biochemical and analytical determinations. 
 
Determination of TAG 
Total lipid was extracted from frozen liver tissues by the method of Bligh and Dyer (19). 
TAG was separated by TLC on silica gel G plates, which were developed with 
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n-hexane/diethyl ether/acetic acid (80:30:1, by vol.). After visualization by spraying 0.001% 
(w/v) primuline in 80 % acetone, the regions that corresponded to TAG were scraped off and 
transferred to tubes. TAG was extracted from silica gel as described previously (18). The TAG 
extract was dried under a flow of nitrogen and re-dissolved in isopropanol–chloroform (9:1, 
v/v) containing 9% (v/v) Triton X-100, and then assayed for TAG concentration using a 
commercially available kit (Triglyceride E-Test Wako; Wako Chemicals, Osaka). TAG in the 
serum was directly determined using the kit (Triglyceride E-Test Wako). 
 
Determination of fibric acids 
One part of the liver was homogenized in nine volumes of 0.25 M sucrose–1 mM 
EDTA–10 mM potassium phosphate buffer (pH 7.4) in a Potter glass-Teflon homogenizer. 
Fibric acids were extracted and analyzed as described previously (20). In brief, fibric acids 
were extracted into n-hexane–ethyl acetate (85:15, by vol.) from liver homogenates (10 mg of 
liver) after acidification with 0.5 M HCl, back-extracted with 0.1 M disodium hydrogen 
phosphate, and then re-extracted with n-hexane–ethyl acetate after acidification with 0.5 M 
HCl. The obtained fibric acids were derivatized with BrMDMC and 18-crown-6-ether, and 
were separated isocratically on a reversed phase with acetonitrile–water (43:57, v/v) for 
derivatives of clofibric acid and bezafibric acid and with acetonitrile–water (46:54, v/v) for 
derivatives of clofibric acid and fenofibric acid by high-performance liquid chromatography 
with fluorescence detection (excitation at 340 nm; emission at 425 nm). 
 
Quantitation of mRNA 
For the determination of mRNA, one portion of the liver was frozen in liquid nitrogen 
and then stored at –80°C. Total RNA was isolated from the liver tissues using QIAzol reagent 
and RNeasy kit (QIAGEN, Hilden, Germany). cDNA was synthesized from 500 ng of total 
RNA, as described previously (21). PCR amplification was carried out using SYBR Premix 
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EX Taq (2x, Perfect Real Time; Takara Bio Inc., Otsu). The amplification and detection were 
performed with Applied Biosystems Step One PlusTM real-time PCR system (Life 
Technologies Corp., Carlsbad, CA, USA). The thermal cycling program was as follows: 10 s 
denaturation step at 95°C followed by 50 cycles of 5 s denaturation at 95°C, and 34 s 
annealing at 60°C. Melting curve analysis was performed to confirm the real-time quantitative 
RT-PCR products. Changes in gene expression were calculated using the comparative 
threshold cycle (Ct) method. Ct values were first normalized by subtracting the Ct value 
obtained from β-actin (control). The sequences of primers used in this study are listed in Table 
1. 
 
Western blot analysis 
Western bolt analyses were performed essentially according to Reid et al. (14). Briefly, 
one portion of the liver was homogenized in RIPA lysis buffer (25 mM Tris–HCl (pH 7.6), 
150 mM NaCl, 1% NP40, 1% sodium deoxycholate and 0.1% sodium dodecyl sulfate 
supplemented with protease inhibitors (aprotinin at 2 μg/ml, bestatin at 13.8 μg/ml, leupeptin 
at 10 μg/ml, pepstatin at 5 μg/ml and AEBSF at 250 μg/ml)) using a Polytrone RT2100 
homogenizer (Kinematica, Luzern, Switzerland) at 4°C, incubated on ice for 30 min and 
centrifuged at 10,000 x g for 10 min at 4°C. The supernatants were recentifuged at 10,000 x g 
for 10 min, and the resulting supernatants were collected for determination of protein 
concentration using BCA protein assay reagent (Thermo Fisher Scientific, Waltham, MA, 
USA) using BSA as a standard. Total tissue lysates containing 10 μg of protein were boiled in 
0.063 M Tris–HCl (pH 6.8) containing 5% (v/v) 2-mercaptoethanol, 2% sodium dodecyl 
sulfate, 6% (v/v) glycerol and 0.02% bromophenacylblue. The denatured samples underwent 
sodium dodecyl sulfate/polyacrylamide gel electrophoresis with 8% acrylamine. Proteins 
were then transferred onto a polyvinylidene difluoride membrane (Amersham Hybond-P 
PVDF Transfer membrane; GE Healthcare, Buckinghamshire, England) using a Trans-Blot 
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Semi-Dry Transfer Cell (Bio-Rad Inc., Hercules, CA, USA). Membranes were incubated at 
room temperature for 30 min with blocking buffer (Tris-buffered saline (pH 7.6) containing 
0.1% Tween 20, 5% skim milk and 1% BSA). Membranes were incubated with anti-ATGL 
(F-7) mouse monoclonal IgG. After 12 h of incubation, membranes were washed three times 
in Tris-buffered saline (pH 7.6) containing 0.1% Tween 20. Membranes were then incubated 
with a secondary antibody conjugated to horseradish peroxidase (anti-mouse IgG HRP-linked 
antibody) for 2 h. Membranes were washed three times with Tris-buffered saline (pH 7.6) 
containing 0.1% Tween 20. Proteins were visualized using the ECL Prime Western Blotting 
Detection Reagent (GE Healthcare) and detected in a LAS-1000 (GE Healthcare). 
 
Measurement of TAG hydrolase activity 
Cytoplasmic fraction was prepared as previously described (12, 22). About 1 g of the 
liver was homogenized in four volumes of homogenate buffer (0.5 M sucrose, 1 mM EDTA, 
20 mM Tris-HCl (pH 7.4), 1 mM dithioerythritol, leupeptin at 20 μg/ml, antipain at 2 μg/ml 
and pepstatine at 1 μg/ml) using a Dounce homogenizer. The homogenates were centrifuged 
at 1,000 g for 10 min. The resulting supernatant was applied to a discontinuous gradient of 
0.25 M, 0.5 M (the supernatant of homogenate) and 1.5 M sucrose. The tubes were 
centrifuged at 100,000 g in a swinging bucket rotor for 3 h. The 0.5 M sucrose fraction was 
collected and used as cytoplasmic fraction. TAG hydrolase activity was measured essentially 
as previously described (12) with some modifications. Substrate was prepared as described 
previously (23). Briefly, 2.96 mg (3 μCi) of [14C]triolein (final raidospecific activity, 0.9 
μCi/μmol) and 300 μg of phosphatidylcholine/phosphatidylinositol (3:1) were mixed. After 
drying under nitrogen and then in vacuo, the mixture was emulsified by sonication with a 
sonicator (Astrason ultrasonic processor XL2020; Misonix Inc.; Farmingdale, NY, USA) in 
1.5 ml of 0.1 M potassium phosphate buffer (pH 7.0). After completed sonication, to the 
solution was added 0.5 ml of 20% (w/v) BSA (defatted) in 0.1 M potassium phosphate buffer 
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(pH 7.0), and the mixture was gently vortex-mixed. For each assay, 100 μl substrate solution 
with 50 μl cytoplasmic fraction and 50 μl buffer (20 mM potassium phosphate, 1 mM EDTA, 
1mM dithioerythritol and 0.02% (w/v) defatted BSA, pH 7.0) were incubated for 60 min at 
37°C. The incubation mixture without cytoplasmic fraction was run simultaneously. Reaction 
was stopped by adding 6 ml of chloroform/methanol (1:2, v/v), and then oleic acid (56.4 μg as 
ethanol solution) and diolein (124.2 μg as ethanol solution) were added as carriers. After 
mixing, 1.4 ml of 0.1M HCl was added to the mixture. Lipids were extracted as previously 
described (19). The extracts were taken to dryness under a flow of nitrogen, and the dried 
lipids were dissolved in a known volume of chloroform/methanol (1:1, v/v). An aliquot of the 
solution was used to measure total radioactivity in the extract. Another aliquot of the solution 
was subjected to TLC on silica gel G plates, which were developed with n-hexane/diethyl 
ether/acetic acid (80:30:1, by vol.). After visualization by spraying primuline solution, the 
regions that corresponded to fatty acid, diacylglycerol and monoacylglycerol were scraped off 
and transferred to tubes. These lipids were extracted from silica gel as described previously 
(18), and the extracts obtained were transferred to vials. After being dried under a flow of 
nitrogen, the residues obtained were dissolved in scintillator, and radioactivities were counted 
to calculate the amounts of TAG hydrolyzed. The control value, which was obtained from the 
incubation without cytoplasmic fraction, was subtracted to give the net TAG hydrolyzed by 
cytoplasmic fraction. 
 
Statistical analysis 
Data were analyzed by one-way ANOVA followed by Scheffé’s multiple range test as a 
post hoc test. Differences were considered significant at P-value < 0.05. Linear regression 
analysis was performed to evaluate the correlation between two variables. 
 
Results 
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 Body weight and daily food intake of the rat were measured throughout the treatment. 
The body weights of treated rats were similar to that of control (Fig. 1A). Daily food intake 
was not significantly changed by the treatment (Fig. 1B). On the basis of these data, the 
amounts of fibrate taken in by each rat were calculated (Fig. 1C, D and E). There were very 
strong linear correlations between the % of fibrate in diet and the calculated dose. These 
results indicated that the dietary concentrations of fenofibrate at 0.025, 0.05, 0.1 and 0.2% 
(w/w) correspond to, respectively, 15.2 ± 2.7, 34.3 ± 5.0, 67.7 ± 10.4 and 133.4 ± 22.1 mg/kg 
body weight per day, that those of bezafibrate at 0.025, 0.05, 0.1 and 0.2% (w/w) correspond 
to, respectively, 17.0 ± 3.2, 34.0 ± 5.3, 66.6 ± 11.7 and 140.6 ± 25.5 mg/kg body weight per 
day, and that those of clofibric acid at 0.05, 0.1, 0.15, 0.2 and 0.3% (w/w) correspond to, 
respectively, 34.1 ± 4.9, 66.4 ± 16.4, 98.8 ± 20.2, 134.5 ± 30.8 and 202.1 ± 40.2 mg/kg body 
weight per day. Thus, substantially, there was no difference in the calculated dose among the 
animal groups treated with the three fibrates. These results may allow us to compare the 
effects of three fibrates on TAG levels in the liver. 
 
Dose- and time-dependent reduction of hepatic TAG by fibrates 
Contents of TAG in the liver of rats that were treated with fenofibrate, bezafibrate and 
clofibric acid at various doses for 14 days were estimated; the treatments with the three 
fibrates significantly decreased hepatic contents of TAG in dose-dependent manners (Figs. 2A, 
C, E). At a dietary concentration of 0.1% (w/w), TAG contents in the liver of rats that were 
treated with fenofibrate and bezafibrate were 48 and 58%, respectively, of those of the control. 
Although the treatments of rats with 0.1% (w/w) clofibric acid did not significantly reduce 
hepatic TAG contents, TAG contents in the liver of rats treated with 0.3% (w/w) clofibric acid 
were 40% of those of the control. The treatments of rats with 0.1% (w/w) fenofibrate, 0.1% 
(w/w) bezafibrate or 0.3% (w/w) clofibric acid reduced hepatic contents of TAG in 
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time-dependent manners (Figs. 2B, D, F). The treatments of rats with fenofibrate and 
bezafibrate significantly decreased serum concentrations of TAG; clofibric acid tended to 
reduce it, effects that were not significant (Fig. 3). 
To gain insight into the molecular basis of TAG reduction by fibrates, mRNA levels of 
key enzymes involved in the metabolism of fatty acids and TAG in the liver of rats that were 
fed on a diet containing 0.1% (w/w) fenofibrate, 0.1% (w/w) bezafibrate or 0.3% (w/w) 
clofibric acid for 14 days were estimated (Table 2). The treatments with the fibrates 
up-regulated the expression of genes encoding enzymes and proteins participating in the 
degradation of TAG and fatty acids (adipose triglyceride lipase (ATGL), comparative gene 
identification-58 (CGI-58), carnitine palmitoyltransferase 1a (CPT1a), medium-chain 
acyl-CoA dehydrogenase (MCAD), long-chain acyl-CoA dehydrogenase (LCAD) and 
acyl-CoA oxidase 1 (Acox1)). With regard to proteins and enzymes involved in 
transport/trafficking of fatty acids, treatments with the fibrates caused significant increases in 
mRNA levels of fatty acid translocase (FAT/CD36), fatty acid transport protein (FATP) 2, 
fatty acid binding protein1 (FABP1), long-chain acyl-CoA synthetase (ACSL) 1 and ACSL3. 
By contrast, FATP5 was down-regulated by fibrates. Fibrates did not change the mRNA levels 
for either FATP4, plasma membrane-associated fatty acid binding protein (FABPpm) or 
ACSL5, except for slight up-regulation of ACSL5 expression by fenofibrate. With regard to 
fatty acid synthesis, the levels of mRNAs encoding fatty acid elongase 6 (Elovl6) and 
stearoyl-CoA desaturase 1 (SCD1) were elevated by the three fibrates, but that of fatty acid 
synthease (FAS) was increased by only fenofibrate. As for enzymes involved in glycerolipid 
synthesis, fenofibrate and bezafibrate slightly augmented mRNA level of GPAT4 while that 
was decreased by clofibric acid. Gene expression of DGAT2 was slightly down-regulated by 
the three fibrates; on the other hand, fenofibrate alone increased mRNA level of DGAT1. 
 
Up-regulation of ATGL by fibrates 
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Levels of mRNA encoding ATGL in the liver of rats that were treated with fenofibrate, 
bezafibrate and clofibric acid at various doses for 14 days were estimated (Figs. 4A, C, E). At 
relatively low doses, fenofibrate and bezafibrate elevated the mRNA level of ATGL more 
potently than clofibric acid did. The mRNA level of ATGL rose with an increasing dose of 
fibrates, and almost reached a plateau at a dose of fenofibrate and bezafibrate of 0.1% (w/w) 
and at a dose of clofibric acid of 0.15% (w/w). When comparing the potency at a dietary 
concentration of 0.1% (w/w), fenofibrate, bezafibrate and clofibric acid increased the mRNA 
level of ATGL by 4.5-, 4.3- and 1.1-fold, respectively. Moreover, the treatments of rats with 
the three fibrates increased the level of mRNA encoding ATGL in time-dependent manners 
(Figs. 4B, D, F). The level of mRNA for CGI-58 in the liver was also increased by the 
treatments of rats with the three fibrates in dose- and time-dependent manners (Fig. 5). To 
estimate the relationship between the level of ATGL mRNA and the concentration of TAG in 
the liver, linear regression analysis was performed (Fig. 6). There was a fairly strong inverse 
correlation between the mRNA level of ATGL and the content of TAG (r2 = 0.6808). 
We next measured TAG hydrolase activity in cytoplasmic fraction of livers of the rats, 
that were treated with three fibrates, with [14C]triolein as a substrate. The treatment with 0.1% 
(w/w) fenofibrate and 0.3% (w/w) clofibric acid for 14 days increased TAG hydrolase activity 
by 1.8- and 1.6-fold, respectively, compared with that of the control, and the treatment with 
0.1% (w/w) bezafibrate tended to elevate the activity by1.4-fold (Fig. 7). The effects of the 
three fibrates on the ATGL protein level in the liver were also evaluated by Western blot 
analysis (Fig. 8). The ATGL protein levels in the liver of rats, which were fed on a diet 
containing one of 0.1% (w/w) fenofibrate, 0.1% (w/w) bezafibrate and 0.3% (w/w) clofibric 
acid for 14 days, were 2.7-, 3.8- and 3.5-fold, respectively, greater than that of the control. 
To understand possible involvement of peroxisome proliferator-activated receptor α 
(PPARα) in the induction of ATGL, the relationship between level of the mRNA encoding 
acyl-CoA thioesterase 1 (Acot1), a typical PPARα target gene, and that encoding ATGL was 
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examined (Fig. 9). Upon the treatment of rats with various doses of fenofibrate, bezafibrate 
and clofibric acid, the level of the mRNA for Acot1 in the liver rose with increasing dose (Fig. 
9A). Linear regression analysis revealed a strong correlation between the mRNA level of 
Acot1 and that of ATGL (r2 = 0.9383) (Fig. 9B) 
 
Potency of fibric acids to induce ATGL and to reduce TAG in the liver 
To estimate the potency of fibric acids to up-regulate ATGL and reduce TAG in the liver, 
hepatic concentrations of fibric acids, active forms of fibrates, in the liver of rats treated with 
various doses of fibrates for 14 days were measured (Fig. 10A). There was a large difference 
in hepatic concentration between clofibric acid and fenofibric acid or bezafibric acid. 
However, the concentration of clofibric acid in the liver of rats treated with 0.3% (w/w) 
clofibric acid was almost the same as those of fenofibric acid and bezafibric acid in the livers 
of rats fed on a diet containing 0.1% (w/w) fenofibrate or 0.1% (w/w) bezafibrate. Figure 10B 
shows the relationship between concentration of fibric acids and the mRNA level of ATGL in 
the liver; there was a strong correlation between these two variables (r2 = 0.9025). Moreover, 
a fairly good inverse correlation was observed between fibric acid concentration and TAG 
content in the liver (r2 = 0.8008) (Fig. 10C). 
 
Discussion 
 
The present study clearly showed that three fibrates, fenofibrate, bezafibrate and clofibric 
acid, reduced the hepatic concentration of TAG in dose- and time-dependent manners, 
although conflicting results appear in the literature concerning the effects of fenofibrate on 
hepatic TAG content (11, 24). In the current study, fenofibrate behaved as the most powerful 
hepatic TAG suppressor, while clofibric acid was the least potent. The order of potency in 
decreasing hepatic TAG (fenofibrate ≥ bezafibrate > clofibric acid) did not always agree with 
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the reported manifestation of PPARα activation (25). To date, the TAG-reducing activity of 
fibrates has been considered to be mainly mediated by the elevation of peroxisomal and 
mitochondrial fatty acid degradation. Nevertheless, the detailed mechanism underlying the 
action of fibrates to reduce hepatic TAG is not fully understood. Hepatic TAG concentration is 
maintained by a carefully regulated balance of the two predominant metabolic pathways of 
synthesis and disposal in the liver. Namely, hepatic TAG content could be controlled by (i) de 
novo fatty acid synthesis, (ii) delivery of fatty acids from extra-hepatic sources, (iii) TAG 
synthesis, (iv) fatty acid β-oxidation, and (v) secretion of very-low-density lipoprotein 
(VLDL). To deal with these possibilities, we measured the expression of genes encoding 
enzymes and proteins for lipid degradation, fatty acid translocation/trafficking and lipogenesis. 
The expression of genes for enzymes involved in oxidation and utilization of fatty acids, 
CPT1a, MCAD, LCAD, Acox1 and ACSL1, was significantly up-regulated by all the three 
fibrates. These results strongly suggest the increased degradation of fatty acids in hepatocytes, 
which is generally considered to be the cause of the reduction of hepatic TAG by fibrates (26, 
27). As for the contributions of mitochondrial and peroxisomal β-oxidation to total fatty acid 
β-oxidation in the liver, Mannaerts et al. (28) has estimated the contribution of peroxisomal 
β-oxidation to total fatty acid oxidation to be less than 10% in the living hepatocytes from 
both control and clofibrate-treated rats, despite the fact that activity of peroxisomal 
β-oxidation in liver homogenates is strikingly increased by the treatment of rats with 
clofibrate. The same authors demonstrated that the activity of mitochondrial β-oxidation is 
increased several fold in both the liver homogenates and the living hepatocytes by the 
treatment of rats with clofibrate. Our current results that fibrates up-regulated the expression 
of the gene for CPT1a are in good agreement with the results of Mannaerts et al. (28) because 
CPT1a is a critical rate-determining regulator of mitochondrial β-oxidation in the liver (29). A 
previous study demonstrated that a moderate up-regulation of CPT1a is sufficient to 
substantially reduce hepatic TAG (30). Therefore, it is likely that mitochondrial β-oxidation, 
 15 
in particular CPT1a, plays a greater role in fatty acid degradation in the liver of fibrate-treated 
rats, whereas the up-regulation of Acox1, a rate-limiting enzyme of peroxisomal β-oxidation, 
by fibrates plays a physiologically less dominant role in fatty acid catabolism. Collectively, it 
might be conceivable that up-regulation of CPT1a by fibrates may be a cause for reduction of 
hepatic concentration of TAG by the drugs. However, it should be pointed out two facts here. 
One is the finding of Lankester et al. (31) who suggested that rat hepatocytes preferentially 
oxidized fatty acid derived from TAG hydrolysis versus those derived from exogenous uptake. 
The other is that TAG is required to be hydrolyzed to fatty acids before the fatty acids undergo 
β-oxidation. Until recently, the first step of TAG degradation in the liver was not fully 
understood. Growing evidence has been emerged indicating that ATGL plays a pivotal role in 
regulating TAG content in the liver (11 - 14 ). Recent studies demonstrated that, despite the 
fact that ATGL expression in the liver is relatively low compared with that in other tissues, 
hepatic absence of ATGL causes massive accumulation of TAG in the liver (11 - 13) and that 
the overexpression of ATGL in the liver abolishes hepatic TAG stores (13, 14). Namely, fatty 
acids released from TAG by ATGL are channeled to oxidation rather than to other metabolic 
pathways (14). Thus, the existing evidence strongly suggest that ATGL dominates the process 
of reducing hepatic TAG and that fatty acid oxidation by mitochondria and peroxisomes is 
secondary to TAG hydrolysis by ATGL with regard to TAG catabolism. In this context, among 
the biochemical manifestations observed in the current study following the administration of 
fibrates, we consider the importance of the modifications in ATGL caused by fibrates. The 
present results clearly revealed that the fibrates augmented the expression of ATGL 
concomitantly with elevation of the gene expression of CGI-58, a cofactor of ATGL (10). The 
manifestation was dose- and time-dependent and commonly exhibited by the three fibrates; 
the order of potency in inducing hepatic ATGL was fenofibrate ≥ bezafibrate > clofibric acid 
in vivo. Moreover, the present study confirmed that the levels of activity and protein of ATGL 
were also increased by the treatment of rats with the three fibrates. Importantly, there was a 
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fairly strong inverse correlation between ATGL mRNA level and TAG content in the liver. 
These results, taken together, lead to the conclusion that ATGL is a key player that triggers 
TAG degradation by fibrates. On the one hand, it is also more likely that fibrates affected 
TAG synthesis. There are two sources of fatty acids as substrates for TAG synthesis. One is 
the fatty acids synthesized de novo in the liver, and the other is the fatty acids taken up from 
circulation. The present study confirmed that expression of the FAS gene (de novo fatty acid 
synthesis) was largely unchanged; accordingly, the supply of de novo synthesis of palmitic 
acid may not be affected by fibrate treatments. On the other hand, supply of fatty acids from 
circulation to hepatocytes is most likely to be increased by fibrates because the expression of 
FAT/CD36 gene, a main fatty acid transporter in hepatocytes (32), was strikingly up-regulated 
and that of FATP2 was significantly augmented by fibrates. The current study showed that 
ACSL3 was significantly up-regulated by fibrates. Interestingly, a recent study using lined 
cells showed that ACSL3 is localized to the endoplasmic reticulum and cytosolic lipid 
droplets and that ACSL3 not only esterifies fatty acids with CoA but also is involved in the 
cellular uptake of fatty acids, presumably by indirect metabolic trapping, despite the fact that 
ACSL3 is not a fatty acid transporter (33). Therefore, it is likely that ACSL3 up-regulated by 
fibrates activates and channels fatty acids toward TAG synthesis pathway in the liver. 
Moreover, in accordance with previous findings (34, 35), fibrates markedly elevated the 
expression of both Elovl6 and SCD1 participating in oleic acid synthesis from palmitic acid 
and stearic acid, results that suggest increased formation of oleic acid not only from palmitic 
acid synthesized de novo but also from palmitic acid and stearic acid taken up from 
circulation. The latter had been demonstrated by our previous study that the in vivo 
conversion of [14C] stearic acid to [14C] oleic acid in the liver is stimulated by the treatment of 
rats with clofibric acid (36, 37). Therefore, despite slight down-regulation of DGAT2 
expression by fibrates, it is most likely that a massive amount of oleic acid is formed and 
available for the formation of TAG in the liver of rats treated with fibrates because oleic acid 
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is known to be incorporated into TAG more preferentially than other fatty acids (38 - 40). 
Since a previous study showed that fatty acids released from TAG by ATGL are more readily 
oxidized than those supplied as fatty acids in media for cultured cells (31), it is more likely 
that fatty acids derived from TAG hydrolysis mediated by ATGL underwent β-oxidation, the 
activity of which was markedly increased by the treatment with fibrates. As for the secretion 
of VLDL-TAG, the present study showed that fenofibrate and bezafibrate decreased serum 
concentration of TAG and that clofibric acid tended to reduce it, but not significantly. These 
results suggest that the changes in VLDL-TAG secretion into circulation are not a cause for 
the fibrate-mediated decrease in hepatic TAG levels. 
The ATGL gene is considered to be a PPARα target (41) and fibrates are known to be 
PPARα agonists (25), implying the possibility that fibrates induced ATGL in the liver through 
the activation of PPARα. However, little information is available with respect to potency of 
fibrates to activate PPARα in the liver in vivo because the potency as a PPARα agonist is 
generally estimated by reporter assay employing cultured cells (25). Since it is difficult to 
provide definite experimental proof that the induction of ATGL by fibrates working in the 
liver is quantitatively mediated through the activation of PPARα in vivo, the present study 
employed an approach to estimate the in vivo potency of the three fibrates by the 
determination of the increase in mRNA abundance of the Acot1 gene. Acot1 encodes 
long-chain acyl-CoA thioesterase 1 (42, 43), which was found to be one of two different 
peroxisome proliferator-inducible palmitoyl-CoA hydrolases in rat liver cytosol and is not a 
constitutive enzyme in the liver (44). Moreover, Acot1 has been demonstrated to be regulated 
by fibrate treatment through the action of PPARα in vivo (43). The finding may indicate that 
Acot1 can be used as a likely outcome of activated PPARα working functionally in vivo in the 
liver. The current results demonstrated a strong correlation between the mRNA levels of 
Acot1 and ATGL in the liver of rats treated with the three fibrates. This result is not direct 
proof, but suggests the possible involvement of PPARα activation in ATGL induction by 
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fibrates in the liver. 
ATGL overexpression enhances TAG hydrolysis, and the consequential release of fatty 
acids drives PPARα activity in rat hepatocytes (11, 14, 45); conversely, ATGL deficiency 
leads to down-regulation of PPARα target genes in the liver (11). These findings strongly 
suggest that ATGL is critically involved in the hepatocellular mobilization of fatty acids and 
fatty acid signaling (45). ATGL resides predominantly on cytosolic lipid droplets and on 
intracellular membranes (22). How fatty acids traffic from the lipid droplets to the nucleus to 
activate PPARα remains unclear, but it is plausible that the process involves FABP (46). The 
present study showed that fibrates increased expression of the FABP1 gene, a result that is in 
good agreement with our previous finding that the treatment of rats with clofibric acid 
induced FABP protein in the liver (47). Various types of fatty acids have been shown to 
activate PPARα (48, 49). Therefore, it is logical to speculate that fatty acids released from 
cytosolic lipid droplets by ATGL are channeled to two metabolic pathways. One is that the 
fatty acids are transported by FABP to mitochondria, where they are exclusively utilized for 
β-oxidation. The other is that the released fatty acids are similarly transported to the nucleus, 
where they activate PPARα as its ligand (45), activation of the transcription factor that relays 
further stimulation of fatty acid uptake (FAT/CD36), fatty acid trafficking (FABP1), fatty acid 
activation (ACSL1, 3), mitochondrial β-oxidation (CPT1a, MCAD, LCAD) and peroxisomal 
β-oxidation (Acox1), and ATGL as well. Thus, ATGL may further expand this positive 
feedback loop interplaying among PPARα, ATGL and β-oxidation system in hepatocytes. In 
doing so, hepatic TAG decreases.  
The present study showed that there are differences in the in vivo potency to induce 
ATGL and to reduce hepatic TAG among fenofibrate, bezafibrate (also referred to as 
bezafibric acid) and clofibric acid. However, our present study has uncovered strong 
correlations not only between the hepatic concentrations of fibric acids irrespective of their 
chemical structures and mRNA levels of ATGL, but also between these and hepatic TAG 
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concentrations. Fibrates, ester forms of fibric acids, are prodrugs, and it is known that they are 
hydrolyzed by hepatic esterase(s) to form active metabolites, fibric acids. Importantly, the 
current results suggest that the three fibric acids, fenofibric, bezafibric and clofibric acids, 
have almost the same potency to induce ATGL, possibly through activation of PPARα in vivo, 
in vivo inside the liver. However, it should be noted here that the three fibrates also displayed 
considerable differences in the mode of action on the expression of genes, which was 
investigated in the present study (as shown in Table 2), despite the fact that intra-hepatic 
concentrations of fenofibric acid, bezafibric acid and clofibric acid were largely the same (as 
shown in Fig. 10A). These results imply that there is some difference in mode of action 
among the three fibrates. 
     Finally, the present study evidently revealed that the three fibric acids exhibit ATGL 
induction and TAG reduction in the liver with largely the same potency. Turpin et al. 
demonstrated that hepatic ATGL production is reduced in several models of rodent obesity 
and that ATGL ablation leads to pronounced steatosis, which is characterized by an 
impairment in fatty acid oxidation, whereas increasing ATGL production in the liver reduces 
hepatic steatosis and mildly enhances liver insulin sensitivity (13). Collectively, these findings 
suggest the possibility that ATGL represents a pharmacological therapeutic target for 
ameliorating NAFLD, and that fibric acids are the likely drugs to ameliorate and/or protect 
against hepatic steatosis associated with insulin resistance. 
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(Figure legends) 
 
Fig. 1.   Effects of fibrates on body weight, food consumption and calculated dose. A: Body 
weight of rats. B: Food consumption of rats. C, D, E: Calculated dose. Rats were fed on a 
standard diet or a diet admixed with fenofibrate at a dietary concentration of 0.025, 0.05, 0.1 
or 0.2% (w/w), bezafibrate at a dietary concentration of 0.025, 0.05, 0.1 or 0.2% (w/w) or 
clofibric acid at a dietary concentration of 0.05, 0.1, 0.15, 0.2 or 0.3% (w/w) for 14 days. 
Values are means ± S.D. (n = 4). The amounts of fibrate taken in by a rat were calculated 
using the regression lines. C, The relationship between the dietary dose and the calculated 
dose of fenofibrate, y = 670.0x - 0.1 (r2 = 0.9997); D, The relationship between the dietary 
dose and the calculated dose of bezafibrate, y = 701.6x - 1.0 (r2 = 0.9992); E, The relationship 
between the dietary dose and the calculated dose of clofibric acid, y = 672.8x - 0.4 (r2 = 
0.9998). 
 
Fig. 2.   Effects of fibrates on TAG concentration in the liver of rats.  A, C, E: The 
dose-dependent reduction of TAG; rats were fed on a standard diet or a diet admixed with 
fenofibrate (A) at a dietary concentration of 0.025 (15.2 ± 2.7 mg/kg body weight per day), 
0.05 (34.3 ± 5.0 mg/kg body weight per day), 0.1 (67.7 ± 10.4 mg/kg body weight per day) or 
0.2% (w/w) (133.4 ± 22.1 mg/kg body weight per day), bezafibrate (C) at a dietary 
concentration of 0.025 (17.0 ± 3.2 mg/kg body weight per day), 0.05 (34.0 ± 5.3 mg/kg body 
weight per day), 0.1 (66.6 ± 11.7 mg/kg body weight per day) or 0.2% (w/w) (140.6 ± 25.5 
mg/kg body weight per day) or clofibric acid (E) at a dietary concentration of 0.05 (34.1 ± 
4.9), 0.1 (66.4 ± 16.4 mg/kg body weight per day), 0.15 (98.8 ± 20.2mg/kg body weight per 
day), 0.2 (134.5 ± 30.8 mg/kg body weight per day) or 0.3% (w/w) (202.1 ± 40.2 mg/kg body 
weight per day) for 14 days. B, D, F: The time-dependent reduction of TAG; rats were fed on 
a diet containing (B) 0.1% (w/w) fenofibrate (67.7 ± 10.4 mg/kg body weight per day), (D) 
 27 
0.1% (w/w) bezafibrate (66.6 ± 11.7 mg/kg body weight per day) or (F) 0.3% (w/w) clofibric 
acid (202.1 ± 40.2 mg/kg body weight per day) for 0, 2, 7 or 14 days. Values are means ± S.D. 
(n = 4). a, b, c Differences in the mean without a common superscript (a, b or c) are statistically 
significant (P < 0.05). 
 
Fig. 3.   Effects of fibrates on TAG concentration in serum. Rats were treated with 
fenofibrate, bezafibrate or clofibric acid at various doses for 14 days. The treatments were the 
same as those described in the legend to Fig. 2A, C and E. A, Fenofibrate; B, bezafibrate; C, 
clofibric acid. 
 
Fig. 4.   Effects of fibrates on mRNA encoding ATGL in the liver of rats. The treatments of 
rats were the same as described in the legend to Fig. 2. A, C, E: The dose-dependent increase 
in ATGL mRNA; A, Fenofibrate; C, bezafibrate; E, clofibric acid. B, D, F: The 
time-dependent increase in ATGL mRNA; B, fenofibrate; D, bezafibrate; F, clofibric acid. 
Values are means ± S.D. (n = 4). a, b, c Differences in the mean without a common superscript 
(a, b or c) are statistically significant (P < 0.05). 
 
Fig. 5.   Effects of fibrates on mRNA encoding CGI-58 in the liver of rats. The treatments of 
rats were the same as described in the legend to Fig. 2. A, C, E: The dose-dependent increase 
in CGI-58 mRNA; A, Fenofibrate; C, bezafibrate; E, clofibric acid. B, D, F: The 
time-dependent increase in CGI-58 mRNA; B, fenofibrate; D, bezafibrate; F, clofibric acid. 
Values are means ± S.D. (n = 4). a, b, c Differences in the mean without a common superscript 
(a, b or c) are statistically significant (P < 0.05). In the absence of a superscript, the 
differences in the means are not significant (P > 0.05). 
 
Fig. 6.   Relationship between ATGL mRNA level and TAG concentration in the liver of rats. 
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○, Control; ●, fenofibrate; □, bezafibrate; ▲, clofibric acid. The relationship between TAG 
concentration (data from Fig. 2A, C and E) and the ATGL mRNA level (data from Fig. 4A, C 
and E) was determined as Y = -1.0629X + 7.8595 (r2 = 0.6808). 
 
Fig. 7.   Effects of fibrates on TAG hydrolase activity in the liver of rats. Rats were fed on a 
standard diet or a diet containing 0.1% (w/w) fenofibrate (67.7 ± 10.4 mg/kg body weight per 
day), 0.1% (w/w) bezafibrate (66.6 ± 11.7 mg/kg body weight per day) or 0.3% (w/w) 
clofibric acid (202.1 ± 40.2 mg/kg body weight per day) for 14 days. Values are means ± S.D. 
(n = 4). a, b Differences in the mean without a common superscript (a or b) are statistically 
significant (P < 0.05). 
 
Fig. 8.   Effects of fibrates on protein expression of ATGL in the liver of rats. Rats were fed 
on a standard diet or a diet containing 0.1% (w/w) fenofibrate (67.7 ± 10.4 mg/kg body 
weight per day), 0.1% (w/w) bezafibrate (66.6 ± 11.7 mg/kg body weight per day) or 0.3% 
(w/w) clofibric acid (202.1 ± 40.2 mg/kg body weight per day) for 14 days. Immunoblot was 
carried out on liver extracts. Liver extracts (10 μg of protein each) were loaded and separated 
by electrophoresis. Visible bands represent ATGL and β-actin as indicated. Quantitation of the 
amount of ATGL was carried out using Multi gauge software (GE Healthcare) and normalized 
by loaded β-actin. Values represent means ± S.D. (n = 4). a, b, c Differences without a common 
superscript (a, b or c) are statistically significant (P < 0.05). 
 
Fig. 9.   Up-regulation of the expression of ATGL gene and Acot1 gene by fibrates in the 
liver. Rats were treated with fenofibrate, bezafibrate or clofibric acid at various doses for 14 
days. The treatments were the same as those described in the legend to Fig. 2A, C and E. ○, 
Control; ●, fenofibrate; □, bezafibrate; ▲, clofibric acid. A: Fibrate-induced elevation of 
Acot1 mRNA level. Values are means ± S.D. (n = 4). * The means (fenofibrate-treated) are 
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significantly different from the control (P < 0.05). § The means (bezafibrate-treated) are 
significantly different from the control (P < 0.05). # The means (clofibric acid-treated) are 
significantly different from the control (P < 0.05). B: The relationship between the ATGL 
mRNA level (data from Fig. 4A, C and E) and the Acot1 mRNA level (data from Fig. 9A) 
was determined as Y = 0.0434X + 0.4045 (r2 = 0.9383). 
 
Fig. 10.   Hepatic concentrations of fibric acids and their potency with respect to 
up-regulation of ATGL mRNA expression and reduction of TAG concentration. Rats were 
treated with fenofibrate, bezafibrate or clofibric acid at various doses for 14 days. The 
treatments were the same as those described in the legend to Fig. 2A, C and E. ○, Control; ●, 
fenofibrate; □, bezafibrate; ▲, clofibric acid. A: The concentrations of active metabolites, 
fibric acids, in the liver. B: The relationship between ATGL mRNA level (data from Fig. 4A, 
C and E) and fibric acid concentration (data from Fig. 10A) was determined as Y = 0.0088X + 
0.6454 (r2 = 0.9025). C: The relationship between hepatic ATG concentration (data from Fig. 
2A, C and E) and fibric acid concentration (data from Fig. 10A) was determined as Y = 
-0.0107X + 7.4985 (r2 = 0.8008). 
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Table 1.  Sequences of primers used for real-time PCR 
Primer (5' - 3') Accession No. 
ATGL F: TCACCAACACCAGCATCCAA NM_001108509 
R: TCCATCTCGGTAGCCCTGTTT 
CGI-58 F: TGCATAGATGGCAACTCTGGC NM_212524 
R: ATACACATAATGCCCTGCCCC 
CPT1a F: AAGGCAGCGTTCTTCGTGA NM_031559 
R: GTCAAAGCATCTTCCATGC 
MCAD F: CTTTGCCTCTATTGCGAAGGC J02791 
R: TCCGAAAATCTGCACAGCATC 
LCAD F: TGTATTGGTGCCATAGCCATGA L11276 
R: CCCAGACCTTTTGGCATTTGT 
Acox1 F: ACTACGACGACCTCCCCAAGA NM_031315 
R: TGGCCACGCAGGTAGTTCA 
FAT/CD36 F: CGAAGGCTTGAATCCTACCG NM_031561 
R: TGTTGACCTGCAGTCGTTT 
FATP2 F: TTCAACAGTGGCGATCTCCTG NM_031736 
R: ACCGGAAGGTGTCTCCAACT 
FATP4 F: CCTGGTGTACTATGGATTCCGC NM_001100706 
R: GCTGAAAACTTCTTCCGGATCA 
FATP5 F: TTGCGAACGTACGGCAAGTAG NM_024143 
R: AAGGCGGTCTCGGAAGTAGAAG 
FABPpm F: TCTGCCAATCCTATGCCAA NM_013177 
R: CACCCTTTTGGCTTCTTC 
FABP1 F: CGGCAAGTACCAAGTGCAGAG BC086947 
R: CTGACACCCCCTTGATGTCCT 
ACSL1 F: TCAGAGCAGTTCATCGGCATC NM_012820 
R: GTCGGTTCCAAGCGTGTCATA 
ACSL3 F: GGTGGCCAAAATGTGACAATG NM_057107 
R: AAACTCTCCAATATCGCCAGT 
ACSL5 F: CAAACATGGCTGCTTTCCTCA NM_053607 
R: ACCCTGGACAAGCCTCTCAAA 
FAS F: CGCCGACCAGTATAAACCCA M76767 
R: GTTGTAATCGGCACCCAAGTC 
SCD1 F:TCACCTTGAGAGAAGAATTAGCA J02585 
R: TTCCCATTCCCTTCACTCTGA 
Elovl6 F: AGAACACGTAGCGACTCCGAA AB071986 
R: CAAACGCGTAAGCCCAGAAT 
DGAT1 F: CCGTGGTATCCTGAATTGGT NM_053437 
R: GGCGCTTCTCAATCTGAAAT 
DGAT2 F: ATCTTCTCTGTCACCTGGCT NM_001012345 
R: ACCTTTCTTGGGCGTGTTCC 
GPAT1 F: AGACACAGGCAGGGAATCCAC AF021348 
R: AATTCCCGGAGAAGCCCAG 
GPAT4 F: TTGGAGTCCTGGAATTTGCTGA NM_001047849 
R: GGCTAATCCCTGTGAATGCCA 
Acot1 F: ACTACGACGACCTCCCCAAGA NM_031315.1 
 R: TGGCCACGCAGGTAGTTCA  
β-Actin F: TGCAGAAGGAGATTACTGCC V01217 
 R: CGCAGCTCAGTAACAGTCC  
    
Table 2.  Effects of fibrates on gene expression in the liver 
 
Genes Control Fenofibrate Bezafibrate Clofibric acid 
Lipid degradation     
ATGL 1.0 ± 0.05 a  4.45 ± 0.69 b  4.25 ± 0.82 b  3.32 ± 0.12 b 
 CGI-58 1.0 ± 0.12 a  3.95 ± 0.24 b  3.13 ± 0.87 bc  2.10 ± 0.96 ab 
 CPT1a 1.0 ± 0.28a  2.95 ± 0.44b  3.19 ± 0.37b  2.76 ± 1.24b 
 MCAD 1.0 ± 0.18a  4.53 ± 0.58b  3.58 ± 0.33bc  2.63 ± 0.64c 
 LCAD 1.0 ± 0.40 a  3.68 ± 0.30 b  3.39 ± 0.40 b  2.88 ± 0.46 b 
 Acox1 1.0 ± 0.06 a 27.56 ± 3.95 b  33.08 ± 10.58 b  9.42 ± 2.52 a 
     
Fatty acid trafficking     
 FAT/CD36 1.0 ± 0.32a 17.26 ± 1.17b  9.32 ± 1.77c 23.05 ± 3.67d 
 FATP2 1.0 ± 0.02a  5.15 ± 0.65b  4.24 ± 0.36b  4.26 ± 1.11b 
 FATP4 1.0 ± 0.09 1.34 ± 0.35  1.35 ± 0.25  1.14 ± 0.30 
 FATP5 1.0 ± 0.09a  0.38 ± 0.08b  0.41 ± 0.08b  0.33 ± 0.11b 
FABPpm 1.0 ± 0.14 1.68 ± 0.30  0.61 ± 0.56  1.46± 0.30 
 FABP1 1.0 ± 0.25a  6.72 ± 0.78b  5.12 ± 0.91c  2.53 ± 0.53d 
ACSL1 1.0 ± 0.15 a  3.64 ± 0.34 b  3.11 ± 0.19 c   2.23 ± 0.22 d 
 ACSL3 1.0 ± 0.05a 10.76 ± 3.39b  7.53 ± 0.76bc  5.05 ± 1.43c 
ACSL5 1.0 ± 0.15a  1.54 ± 0.37b  0.72 ± 0.05a  0.69± 0.13a 
     
Lipogenesis     
FAS 1.0 ± 0.49 a  2.52 ± 1.07 b  1.19 ± 0.27 ab  1.84 ± 0.33 ab 
 SCD1 1.0 ± 0.24 a 17.56 ± 4.58 b 19.84 ± 6.61 b 20.73 ± 1.44 b 
 Elovl6 1.0 ± 0.55 a 18.35 ± 7.43 b 17.60 ± 5.33 b 27.81 ± 9.50 b 
DGAT1 1.0 ± 0.49 a   2.62 ± 1.05 b  1.73 ± 0.83 ab  1.80 ± 0.41 ab 
DGAT2 1.0 ± 0.12 a   0.69 ± 0.09 b  0.75 ± 0.07 b  0.59 ± 0.07 b 
GPAT1 1.0 ± 0.03  1.68 ± 0.33  1.19 ± 0.16 1.12 ± 0.37 
GPAT4 1.0 ± 0.21 a   1.46 ± 0.25 b  1.42 ± 0.12 b  0.49 ± 0.16 c 
        Rats were fed on the standard diet or diet containing 0.1% (w/w) fenofibrate (67.7 ± 10.4 
mg/kg body weight per day), 0.1% (w/w) bezafibrate (66.6 ± 11.7 mg/kg body weight per day) or 
0.3% (w/w) clofibric acid (202.1 ± 40.2 mg/kg body weight per day) for 14 days. Values represent 
means ± S.D. (n =4–6). Differences in horizontal means without a common superscript (a, b, c, 
d) are significant (p < 0.05). In the absence of a superscript, the differences in the means are 
not significant (P > 0.05). 
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